Success Metrics

Clinical Success Rate
85.1%

Based on 165 completed trials

Completion Rate
85%(165/194)
Active Trials
12(5%)
Results Posted
47%(78 trials)
Terminated
29(12%)

Phase Distribution

Ph phase_2
55
23%
Ph phase_1
23
9%
Ph phase_4
59
24%
Ph phase_3
82
34%
Ph not_applicable
15
6%

Phase Distribution

23

Early Stage

55

Mid Stage

141

Late Stage

Phase Distribution234 total trials
Phase 1Safety & dosage
23(9.8%)
Phase 2Efficacy & side effects
55(23.5%)
Phase 3Large-scale testing
82(35.0%)
Phase 4Post-market surveillance
59(25.2%)
N/ANon-phased studies
15(6.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.7%

165 of 202 finished

Non-Completion Rate

18.3%

37 ended early

Currently Active

12

trials recruiting

Total Trials

244

all time

Status Distribution
Active(13)
Completed(165)
Terminated(37)
Other(29)

Detailed Status

Completed165
unknown29
Terminated29
Withdrawn8
Recruiting6
Active, not recruiting6

Development Timeline

Analytics

Development Status

Total Trials
244
Active
12
Success Rate
85.1%
Most Advanced
Phase 4

Trials by Phase

Phase 123 (9.8%)
Phase 255 (23.5%)
Phase 382 (35.0%)
Phase 459 (25.2%)
N/A15 (6.4%)

Trials by Status

not_yet_recruiting10%
recruiting62%
unknown2912%
terminated2912%
active_not_recruiting62%
completed16568%
withdrawn83%

Recent Activity

Clinical Trials (244)

Showing 20 of 244 trialsScroll for more
NCT06533865Phase 3

Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea

Recruiting
NCT03295981Phase 3

Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

Recruiting
NCT07546058Not Applicable

Effect of Local Subperiosteal Zoledronic Acid Injection on the Survival of Orthodontic Miniscrews

Completed
NCT06374459Phase 1

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Recruiting
NCT07471516Phase 1

Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia

Recruiting
NCT06625190Phase 1

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

Recruiting
NCT05058976Phase 4

Romosozumab Use to Build Skeletal Integrity

Active Not Recruiting
NCT06135298Phase 4

FARE Augmentation of Proximal Femoral Fractures With CaS/HA and Systemic ZA

Completed
NCT05666310Phase 4

Muscle Impact of Treating Osteoporosis

Active Not Recruiting
NCT02325414Phase 2

Prevention of Bone Loss After Acute SCI by Zoledronic Acid

Completed
NCT03173976Phase 1

Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial

Active Not Recruiting
NCT04087096Phase 4

Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery

Completed
NCT03735537Phase 4

Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid

Completed
NCT00470223Phase 3

Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma

Active Not Recruiting
NCT03073785Phase 2

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer

Active Not Recruiting
NCT01671774Phase 1

Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer

Completed
NCT00365105Phase 3

Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer

Completed
NCT03336983Phase 2

Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients

Completed
NCT04725422

CHronic Nonbacterial Osteomyelitis International Registry

Recruiting
NCT05405894

Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
244